Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Germie van den Dobbelsteen"'
Autor:
Carlos A. Fierro, Michal Sarnecki, Bart Spiessens, Oscar Go, Tracey A. Day, Todd A. Davies, Germie van den Dobbelsteen, Jan Poolman, Darren Abbanat, Wouter Haazen
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract The safety, reactogenicity, and immunogenicity of 3 doses of ExPEC10V (VAC52416), a vaccine candidate to prevent invasive Escherichia coli disease, were assessed in a phase 1/2a study (NCT03819049). In Cohort 1, ExPEC10V was well tolerated;
Externí odkaz:
https://doaj.org/article/cf2074de9415429ca03e908b467aa4d5
Autor:
Brian D. Johnston, Connie Clabots, Tricia Bender, Stephen B. Porter, Germie van den Dobbelsteen, Jan Poolman, Paul Thuras, James R. Johnson
Publikováno v:
Pathogens, Vol 12, Iss 4, p 603 (2023)
An exceptional gut-colonizing ability may underlie the dramatic epidemiological success of the multidrug-resistant H30R subclone of Escherichia coli sequence type 131 (O25b:K+:H4). In order to inform the development of colonization-preventing measure
Externí odkaz:
https://doaj.org/article/f9589377d0024fa69f49fbbf7122b662
Autor:
Megumi Inoue, Tetsuro Ogawa, Hiroshi Tamura, Yosuke Hagiwara, Yuki Saito, Darren Abbanat, Germie van den Dobbelsteen, Peter Hermans, Stefan Thoelen, Jan Poolman, Patricia Ibarra de Palacios
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 9, Pp 2150-2157 (2018)
This Phase 1, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability and immunogenicity of different doses of ExPEC4V conjugate vaccine (4-16µg Polysaccharide [PS]/serotype) in healthy Japanese particip
Externí odkaz:
https://doaj.org/article/3d23f7a5c4eb41e297ef09fea55d7ac9
Autor:
Krzysztof Trzciński, Debby Bogaert, Anne Wyllie, Mei Ling J N Chu, Arie van der Ende, Jacob P Bruin, Germie van den Dobbelsteen, Reinier H Veenhoven, Elisabeth A M Sanders
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e60520 (2013)
The human nasopharynx is the main reservoir for Streptococcus pneumoniae. We applied conventional and molecular methods to determine the prevalence of S. pneumoniae nasopharyngeal colonization in adults. Paired trans-orally and trans-nasally obtained
Externí odkaz:
https://doaj.org/article/cbc46083fe1d4b6088e76228bbb0989f
Autor:
Joachim Doua, Carlos Fierro, Michal Sarnecki, Bart Spiessens, Oscar Go, Todd Davies, Germie van den Dobbelsteen, Jan Poolman, Wouter Haazen
Publikováno v:
Open Forum Infectious Diseases. 9
Background This Phase 1/2a study (NCT03819049) assessed the safety, reactogenicity, and immunogenicity of 3 doses of VAC52416 (ExPEC10V), a vaccine candidate to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. Methods Dat
Autor:
Jolaine M Wilson, Germie van den Dobbelsteen, Rita Chan, Anthony Romanello, Victor J. Torres, Craig McLahan, Danielle Malone, Matthew Willms, Alessandra Buoninfante, Jeffrey Fernandez, Holly Sanders, Jan Poolman, Jessica Henn, Ashley L. DuMont, Kaitlyn Grubb
Publikováno v:
The Journal of Infectious Diseases. 225:1460-1470
Vaccines against Staphylococcus aureus have eluded researchers for >3 decades while the burden of staphylococcal diseases has increased. Early vaccine attempts mainly used rodents to characterize preclinical efficacy, and all subsequently failed in h
Autor:
Ofer Levy, Jeffrey Fernandez, Selma Wiertsema, Anne Marie Queenan, Peter J. Flynn, Alexandre Fortanier, Jan Serroyen, Brightman Spencer E, Wing Ki Cheng, Juan Camilo Ramírez, Germie van den Dobbelsteen, Jan Poolman, Kellen Fae, Sweta Joshi, David J. Dowling
Publikováno v:
Vaccine
Current acellular-pertussis (aP) vaccines appear inadequate for long-term pertussis control because of short-lived efficacy and the increasing prevalence of pertactin-negative isolates which may negatively impact vaccine efficacy. In this study, we a
Autor:
Darren Abbanat, Enos Bernasconi, Stéphan Juergen Harbarth, Ingrid van den Nieuwenhof, Anette Kuhn, P. Martín, Serge de Vallière, Stefan Thoelen, Rahel Frölich, Germie van den Dobbelsteen, Todd A. Davies, Christoph Hatz, Tanja Hülder, Angela Huttner, Anita M. Dreyer, Volker Viereck, Veronica Gambillara Fonck, Gloria Ryu, Kerstin Kling, Sabine Gröger, Jan Poolman, Cristina Alaimo, Alena Hornacek, David Scheiner, Kellen Fae, Tilemachos Kavvadias
Publikováno v:
The Lancet Infectious Diseases, Vol. 17, No 5 (2017) pp. 528-537
BACKGROUND Escherichia coli infections are increasing worldwide in community and hospital settings. The E coli O-antigen is a promising vaccine target. We aimed to assess the safety and immunogenicity of a bioconjugate vaccine containing the O-antige
Autor:
Bart Spiessens, Darren Abbanat, Stefan Thoelen, Jan Poolman, Patricia Ibarra de Palacios, John E Ervin, Robert W. Frenck, Oscar Go, Wouter Haazen, Laurence Chu, Germie van den Dobbelsteen
Publikováno v:
The Lancet. Infectious diseases. 19(6)
Summary Background ExPEC4V (JNJ-63871860) is a bioconjugate vaccine, containing O-antigens from Escherichia coli serotypes O1A, O2, O6A, and O25B, developed for the prevention of invasive extra-intestinal pathogenic E coli (ExPEC) disease. We aimed t